JanOne (Nasdaq: JAN), a US-based biopharmaceutical company, announced on Thursday that it has named John N Bonfiglio, PhD, as interim president of its JanOne Biotech subsidiary.
Dr Bonfiglio has served at Allergan Pharmaceuticals and Baxter HealthCare and then turned to discovering, promoting and leading smaller biotech ventures. He has served as CEO at Peregrine Pharmaceuticals. He has over 30 years of experience, with achievements including helping Cypress Bioscience reinvent itself as a neuro-pharmaceutical company and, as CEO of Immune Response Corporation, raising over USD50m and restarting clinical trials in HIV and MS. Presently, he is a board member for Avipero and executive board member for Sequella.
Tony Isaac, JanOne's CEO, said, 'We are delighted and honoured to have Dr Bonfiglio join us. His experience in running public biotech companies will prove invaluable to the progress of JanOne. Our entire team looks forward to working with him.'
Audientes partners with Audivista to expand hearing solutions in Middle East and North Africa
Benuvia Operations signs licensing deal with Avernus Pharma
Benuvia Operations signs licensing and supply agreements with Medra Brasil Medicamentos
Castle Biosciences to present data on Melanoma tests at ASDP Annual Meeting
Alchemy partners with PatchRx to improve HIV medication adherence
Gilead expands global access to lenacapavir for HIV prevention
Alume Biosciences names new chief commercial officer
genedrive plc secures initial UK order for Genedrive CYP2C19-ID Kit
Gilead's lenacapavir demonstrates 100% efficacy in HIV prevention trial
Gilead study suggests lenacapavir superior to Truvada
Oxford BioDynamics announces opening of clinical testing facility in UK for prostate screening test
Micron Biomedical names new scientific advisor to CEO
China accepts GSK's Shingrix application for at-risk adults
Takeda's HyQvia approved for maintenance therapy in CIDP patients